Marrow transplantation for severe aplastic anemia with significant renal impairment [3]

Bone Marrow Transplantation

Volumn 39, Issue 5, 2007, Pages 311-313

  Gerrie, A ^a   Marsh, J ^b   Lipton, J H ^a   Messner, H ^a   Gupta, V ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYMETHOLONE; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; APLASTIC ANEMIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANADA; CASE REPORT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LETTER; LOW DRUG DOSE; MALE; MONOTHERAPY; NEPHROTOXICITY; PERICARDITIS; PRIORITY JOURNAL; TERTIARY HEALTH CARE; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; RENAL INSUFFICIENCY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33847298529     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705583     Document Type: Letter

References (10)

1. Buhler LH, Spitzer TR, Sykes M, Sachs PH, Delmonico FL, Tolkoff-Rubin N et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405-1409.
2. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39-44.
3. Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653-656.
4. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61: 1495-1501.
5. Yamamoto R, Kanda Y, Matsuyama T, Oshima, K, Nannya Y, Suguro M et al. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. Bone Marrow Transplant 2000; 26: 685-688.
6. Gupta V, Ball SE, Sage D, Ortin M, Freires M, Gordon-Smith EC et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005; 35: 467-471.
7. Weiss AS, Sandmaier BM, Storer B, Storb R. McSweeney PA. Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6: 89-94.
8. Hamaki T, Katori H, Kami M, Yamato T, Yamakado H, Itoh T et al. Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. Bone Marrow Transplant 2002; 30: 195-198.
9. Imasawa T, Nagasawa R, Utsunomiya Y, Kawamura T, Zhong Y, Makita N et al. Bone marrow transplantation attenuates murine IgA nephropathy: Role of a stem cell disorder. Kidney Int 1999; 56: 1809-1817.
10. Imasawa T. Roles of bone marrow cells in glomerular diseases. Clin Exp Nephrol 2003; 7: 179-185.